Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 5,327 matching trials from the live ClinicalTrials.gov search.
Conditions
Pruritus
Interventions
Cervical Traction Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Scottsdale, Arizona
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Conditions
Polypharmacy, Care Transitions, Geriatric Syndromes
Interventions
Shed-Meds: A Patient-Centered Deprescribing Intervention
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Terminated Phase 2 Interventional Results available

Chemoradiation in Locally Advanced Pancreatic Cancer

NCT00262951
Conditions
Pancreatic Cancer
Interventions
recombinant interferon alfa, cisplatin, fluorouracil, radiation therapy, Resection of tumor
Biological · Drug · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Binimetinib, Docetaxel, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Lecanto, Florida + 9 more
Terminated Phase 2 Interventional Results available

Propranolol in Treating Hypoglycemia Unawareness

NCT03161964
Conditions
Type 1 Diabetes Mellitus
Interventions
Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
Drug
Lead sponsor
Anu Sharma
Other
Eligibility
21 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Conditions
Congenital Adrenal Hyperplasia (CAH)
Interventions
Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Advanced Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
La Jolla, California • Shreveport, Louisiana • Detroit, Michigan
Conditions
Neoplasms
Interventions
CC-90011, Nivolumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New York, New York • Canton, Ohio + 5 more
Conditions
Breast Cancer
Interventions
Exercise
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hematological Malignancies
Interventions
fostamatinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Conditions
GIST and CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Conditions
Metastatic Pancreatic Cancer
Interventions
PEGPH20, Nab-paclitaxel, Gemcitabine, Dexamethasone, Enoxaparin
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 45 more
Conditions
Sphingomyelin Lipidosis
Interventions
GZ402665
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Completed Phase 2 Interventional Results available

Fenfluramine in CDKL5 Deficiency Disorder (CDD)

NCT03861871
Conditions
CDD
Interventions
Fenfluramine Hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
Interventions
PS-341 (VELCADE), Temozolomide, immunoenzyme technique
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
Interventions
Melphalan/HDS, Cisplatin and Gemcitabine
Combination Product · Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Columbus, Ohio • Memphis, Tennessee
Conditions
Asthma
Interventions
Placebo ELLIPTA inhaler, Questionnaire
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more
Conditions
Obsessive - Compulsive Disorder
Interventions
ATTN201 - Low Intensity Focused Ultrasound
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cancer
Interventions
Atezolizumab, Bevacizumab, Alectinib, Cobimetinib, Vemurafenib, FAP IL2V, Venetoclax, Enzalutamide, Pembrolizumab, Sunitinib, Niraparib, Cabozantinib, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
7
States / cities
Aurora, Colorado • Trumbull, Connecticut • Boston, Massachusetts + 3 more